Albéa x NG Biotech - Rapid diagnostic tests
Innovative and committed companies
In Brittany (France), the Albéa Group is proud to collaborate with NG Biotech, manufacturer of rapid diagnostic solutions. In a world disrupted by the COVID-19 pandemic, the two companies are adapting, innovating and committing themselves to public health with a shared ambition: to promote the “Made in France” label and favour local, shorter supply chains.
A pioneering company and leader in rapid diagnostics for antibiotic resistance and women's health, NG Biotech has demonstrated its reactivity and ability to adapt by offering, by the end of March 2020, an innovative solution to contribute to the fight against the COVID-19 pandemic with the development of a serological test.
As for Albéa, the Group has been highly mobilized since the beginning of the health crisis, in particular reorganizing its production around hydroalcoholic gel. The Group has also donated numerous tubes of gel to various organisations.
Today Albéa puts its know-how at the service of NG Biotech. Its factory in Plouhinec, in Brittany, manufactures some of the plastic parts required for the production of rapid diagnostic tests. Thanks to its total mastery of complex injection, Albéa Plouhinec developed, in 4 weeks, multi-cavity molds for the caps and lids of the NG Biotech cassette tests. The first industrialisations were successfully completed at the end of December and production is now accelerating, in line with NG Biotech's commercial strategy.
The Brittany Region is also involved and a stakeholder of this project. Thanks to a subsidy for industrial development, the Plouhinec plant has been able to transform one of its machines to adapt it to the printing of cassette tests.
Cyrille Guégan, Manager of Albéa Plouhinec, adds:
“It is a great pride for the whole team to work on a project as meaningful as public health. In a chaotic economic context, managing to adapt and imagine new opportunities, while highlighting the site's technical expertise in record time, is extremely inspiring.”
Milovan Stankov-Pugès, CEO of NG Biotech, explains:
“The manufacture of plastic parts for our rapid tests in local supply chains with a partner based in Brittany responds to three challenges: to strengthen our industrial independence, to reduce our environmental impact thanks to a considerable reduction in transport, and to support activity and employment in the Breton plastics sector.”